259 related articles for article (PubMed ID: 23049733)
1. An Ep-ICD based index is a marker of aggressiveness and poor prognosis in thyroid carcinoma.
He HC; Kashat L; Kak I; Kunavisarut T; Gundelach R; Kim D; So AK; MacMillan C; Freeman JL; Ralhan R; Walfish PG
PLoS One; 2012; 7(9):e42893. PubMed ID: 23049733
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical analysis based Ep-ICD subcellular localization index (ESLI) is a novel marker for metastatic papillary thyroid microcarcinoma.
Kunavisarut T; Kak I; Macmillan C; Ralhan R; Walfish PG
BMC Cancer; 2012 Nov; 12():523. PubMed ID: 23153310
[TBL] [Abstract][Full Text] [Related]
3. EpCAM nuclear localization identifies aggressive thyroid cancer and is a marker for poor prognosis.
Ralhan R; Cao J; Lim T; Macmillan C; Freeman JL; Walfish PG
BMC Cancer; 2010 Jun; 10():331. PubMed ID: 20579375
[TBL] [Abstract][Full Text] [Related]
4. Nuclear and cytoplasmic accumulation of Ep-ICD is frequently detected in human epithelial cancers.
Ralhan R; He HC; So AK; Tripathi SC; Kumar M; Hasan MR; Kaur J; Kashat L; MacMillan C; Chauhan SS; Freeman JL; Walfish PG
PLoS One; 2010 Nov; 5(11):e14130. PubMed ID: 21152431
[TBL] [Abstract][Full Text] [Related]
5. Nuclear Ep-ICD expression is a predictor of poor prognosis in "low risk" prostate adenocarcinomas.
Assi J; Srivastava G; Matta A; MacMillan C; Ralhan R; Walfish PG
PLoS One; 2015; 10(2):e0107586. PubMed ID: 25695234
[TBL] [Abstract][Full Text] [Related]
6. Nuclear Ep-ICD accumulation predicts aggressive clinical course in early stage breast cancer patients.
Srivastava G; Assi J; Kashat L; Matta A; Chang M; Walfish PG; Ralhan R
BMC Cancer; 2014 Sep; 14():726. PubMed ID: 25265904
[TBL] [Abstract][Full Text] [Related]
7. Biotinidase is a novel marker for papillary thyroid cancer aggressiveness.
So AK; Kaur J; Kak I; Assi J; MacMillan C; Ralhan R; Walfish PG
PLoS One; 2012; 7(7):e40956. PubMed ID: 22911723
[TBL] [Abstract][Full Text] [Related]
8. TROP-2 expression in papillary thyroid cancer: a preliminary cyto-histological study.
Addati T; Achille G; Centrone M; Petroni S; Popescu O; Russo S; Grammatica L; Simone G
Cytopathology; 2015 Oct; 26(5):303-11. PubMed ID: 25164548
[TBL] [Abstract][Full Text] [Related]
9. TROP-2 expression in papillary thyroid carcinoma: Potential Diagnostic Utility.
Simms A; Jacob RP; Cohen C; Siddiqui MT
Diagn Cytopathol; 2016 Jan; 44(1):26-31. PubMed ID: 26481593
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of serum DKK-1 predicts poor prognosis in patients with papillary thyroid cancer.
Zhao YP; Wang W; Wang XH; Xu Y; Wang Y; Dong ZF; Zhang JJ
Genet Mol Res; 2015 Dec; 14(4):18886-94. PubMed ID: 26782539
[TBL] [Abstract][Full Text] [Related]
11. Subcellular differential expression of Ep-ICD in oral dysplasia and cancer is associated with disease progression and prognosis.
Somasundaram RT; Kaur J; Leong I; MacMillan C; Witterick IJ; Walfish PG; Ralhan R
BMC Cancer; 2016 Jul; 16():486. PubMed ID: 27421772
[TBL] [Abstract][Full Text] [Related]
12. TROP-2 immunohistochemistry: a highly accurate method in the differential diagnosis of papillary thyroid carcinoma.
Bychkov A; Sampatanukul P; Shuangshoti S; Keelawat S
Pathology; 2016 Aug; 48(5):425-33. PubMed ID: 27311870
[TBL] [Abstract][Full Text] [Related]
13. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.
Chowdhury S; Veyhl J; Jessa F; Polyakova O; Alenzi A; MacMillan C; Ralhan R; Walfish PG
Oncotarget; 2016 May; 7(22):32318-28. PubMed ID: 27086918
[TBL] [Abstract][Full Text] [Related]
14. The diagnostic significance of trophoblast cell-surface antigen-2 expression in benign and malignant thyroid lesions.
Sadullahoğlu C; Sayıner A; Süren D; Yıldırım HT; Nergiz D; Sezer C; Oruç MT
Indian J Pathol Microbiol; 2019; 62(2):206-210. PubMed ID: 30971541
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of long noncoding RNA NONHSAT037832 in papillary thyroid carcinoma and its clinical significance.
Lan X; Sun W; Zhang P; He L; Dong W; Wang Z; Liu S; Zhang H
Tumour Biol; 2016 May; 37(5):6117-23. PubMed ID: 26611646
[TBL] [Abstract][Full Text] [Related]
16. Association between the HLA-G molecule and lymph node metastasis in papillary thyroid cancer.
Nunes LM; Ayres FM; Francescantonio IC; Saddi VA; Avelino MA; Alencar Rde C; Silva RC; Meneghini AJ; Wastowski IJ
Hum Immunol; 2013 Apr; 74(4):447-51. PubMed ID: 23261411
[TBL] [Abstract][Full Text] [Related]
17. Roles of phosphatidylinositol 3-kinase regulatory subunit alpha, activator protein-1, and programmed cell death 4 in diagnosis of papillary thyroid carcinoma.
Chen X; Wu W; Chen X; Gong X
Tumour Biol; 2016 May; 37(5):6519-26. PubMed ID: 26637226
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic significance of elevated expression of HBME-1 in papillary thyroid carcinoma.
Chen YJ; Zhao RM; Zhao Q; Li BY; Ma QY; Li X; Chen X
Tumour Biol; 2016 Jul; 37(7):8715-20. PubMed ID: 26738867
[TBL] [Abstract][Full Text] [Related]
19. Loss of membranous expression of the intracellular domain of EpCAM is a frequent event and predicts poor survival in patients with pancreatic cancer.
Fong D; Moser P; Kasal A; Seeber A; Gastl G; Martowicz A; Wurm M; Mian C; Obrist P; Mazzoleni G; Spizzo G
Histopathology; 2014 Apr; 64(5):683-92. PubMed ID: 24117877
[TBL] [Abstract][Full Text] [Related]
20. Role of differentially expressed genes and long non-coding RNAs in papillary thyroid carcinoma diagnosis, progression, and prognosis.
Cai WY; Chen X; Chen LP; Li Q; Du XJ; Zhou YY
J Cell Biochem; 2018 Nov; 119(10):8249-8259. PubMed ID: 29968931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
